Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more
Abionyx Pharma SA (ABNX) - Total Liabilities
Latest total liabilities as of June 2025: €7.56 Million EUR
Based on the latest financial reports, Abionyx Pharma SA (ABNX) has total liabilities worth €7.56 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Abionyx Pharma SA - Total Liabilities Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Abionyx Pharma SA Competitors by Total Liabilities
The table below lists competitors of Abionyx Pharma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Relais Group Oyj
HE:RELAIS
|
Finland | €316.94 Million |
|
Hong-Wei Electrical Industry & Co., Ltd.
TWO:4565
|
Taiwan | NT$1.88 Billion |
|
Next Vision Stabilized Systems
TA:NXSN
|
Israel | ILA28.00 Million |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
Poland | zł408.24 Million |
|
Enel Generación Costanera S.A
PINK:EDCFF
|
USA | $102.36 Billion |
|
Ace Technologies Corp
KQ:088800
|
Korea | ₩192.80 Billion |
|
Quantum Corporation
NASDAQ:QMCO
|
USA | $298.20 Million |
|
Invicta Holdings Ltd
PINK:IVCHF
|
USA | $4.15 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Abionyx Pharma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.58 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abionyx Pharma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abionyx Pharma SA (2013–2024)
The table below shows the annual total liabilities of Abionyx Pharma SA from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €6.03 Million | -12.82% |
| 2023-12-31 | €6.91 Million | -20.13% |
| 2022-12-31 | €8.65 Million | -22.42% |
| 2021-12-31 | €11.15 Million | +204.86% |
| 2020-12-31 | €3.66 Million | +2.12% |
| 2019-12-31 | €3.58 Million | -61.46% |
| 2018-12-31 | €9.30 Million | -1.18% |
| 2017-12-31 | €9.41 Million | -34.91% |
| 2016-12-31 | €14.46 Million | +11.98% |
| 2015-12-31 | €12.91 Million | +19.24% |
| 2014-12-31 | €10.82 Million | +39.44% |
| 2013-12-31 | €7.76 Million | -- |